TY - JOUR
T1 - Performance of early pregnancy HbA1c for predicting gestational diabetes mellitus and adverse pregnancy outcomes in obese European women
AU - Immanuel, Jincy
AU - Simmons, David
AU - Desoye, Gernot
AU - Corcoy, Rosa
AU - Adelantado, Juan M
AU - Devlieger, Roland
AU - Lapolla, Annunziata
AU - Dalfra, Maria G
AU - Bertolotto, Alessandra
AU - Harreiter, Jürgen
AU - Wender-Ozegowska, Ewa
AU - Zawiejska, Agnieszka
AU - Dunne, Fidelma P
AU - Damm, Peter
AU - Mathiesen, Elisabeth R
AU - Jensen, Dorte M
AU - Andersen, Lise Lotte T
AU - Hill, David J
AU - Jelsma, Judith G M
AU - Snoek, Frank J
AU - Scharnagl, Hubert
AU - Galjaard, Sander
AU - Kautzky-Willer, Alexandra
AU - VAN Poppel, Mireille N M
N1 - Copyright © 2020. Published by Elsevier B.V.
PY - 2020/10
Y1 - 2020/10
N2 - AIMS: To investigate the performance of early pregnancy HbA1c for predicting gestational diabetes mellitus (GDM) and adverse pregnancy outcomes in obese women.METHODS: Post hoc analysis using data from the Vitamin D And Lifestyle Intervention for GDM prevention trials conducted across 9 European countries (2012-2014). Pregnant women (BMI ≥ 29 kg/m2) underwent a baseline HbA1c and oral glucose tolerance tests at < 20 weeks, 24-28 weeks, and 35-37 weeks. Women with GDM were referred for treatment.RESULTS: Among the 869 women tested, the prevalence of GDM was 25.9% before 20 weeks, with a further 8.6% at 24-28 weeks. The areas under the curves for HbA1c at the two time points were 0.55 (0.50-0.59) and 0.54 (0.47-0.61), respectively. An early HbA1c ≥ 5.7% (39 mmol/mol) (N = 111) showed low sensitivity (18.2%) with 89.1% specificity for GDM before 20 weeks, at 24-28 weeks (sensitivity of 8.0% and specificity of 88.6% after excluding early GDM), and throughout gestation (sensitivity of 15.9% and specificity of 89.4%). The ≥ 5.7% (39 mmol/mol) threshold was significantly associated with concurrent GDM before 20 weeks (adjusted OR (aOR) 2.77(1.39-5.51)) and throughout gestation (aOR 1.72 (1.02-2.89)), but not adverse pregnancy outcomes.CONCLUSIONS: Early pregnancy HbA1c is of limited use for predicting either GDM or adverse outcomes in overweight/obese European women.
AB - AIMS: To investigate the performance of early pregnancy HbA1c for predicting gestational diabetes mellitus (GDM) and adverse pregnancy outcomes in obese women.METHODS: Post hoc analysis using data from the Vitamin D And Lifestyle Intervention for GDM prevention trials conducted across 9 European countries (2012-2014). Pregnant women (BMI ≥ 29 kg/m2) underwent a baseline HbA1c and oral glucose tolerance tests at < 20 weeks, 24-28 weeks, and 35-37 weeks. Women with GDM were referred for treatment.RESULTS: Among the 869 women tested, the prevalence of GDM was 25.9% before 20 weeks, with a further 8.6% at 24-28 weeks. The areas under the curves for HbA1c at the two time points were 0.55 (0.50-0.59) and 0.54 (0.47-0.61), respectively. An early HbA1c ≥ 5.7% (39 mmol/mol) (N = 111) showed low sensitivity (18.2%) with 89.1% specificity for GDM before 20 weeks, at 24-28 weeks (sensitivity of 8.0% and specificity of 88.6% after excluding early GDM), and throughout gestation (sensitivity of 15.9% and specificity of 89.4%). The ≥ 5.7% (39 mmol/mol) threshold was significantly associated with concurrent GDM before 20 weeks (adjusted OR (aOR) 2.77(1.39-5.51)) and throughout gestation (aOR 1.72 (1.02-2.89)), but not adverse pregnancy outcomes.CONCLUSIONS: Early pregnancy HbA1c is of limited use for predicting either GDM or adverse outcomes in overweight/obese European women.
KW - Diagnostic threshold
KW - Gestational diabetes mellitus
KW - Hemoglobin A
KW - Odds Ratio
KW - Pregnancy
KW - Pregnancy outcome
UR - http://www.scopus.com/inward/record.url?scp=85090030724&partnerID=8YFLogxK
U2 - 10.1016/j.diabres.2020.108378
DO - 10.1016/j.diabres.2020.108378
M3 - Journal article
C2 - 32828833
VL - 168
SP - 108378
JO - Diabetes Research and Clinical Practice
JF - Diabetes Research and Clinical Practice
SN - 0168-8227
M1 - 108378
ER -